Psychiatry

Interview with Xue on UK Biobank data linking first-onset depression after age 50 to cognitive deficits and increased dementia risk.

Rapid psychedelic therapies, accelerated TMS protocols, AI-driven care debates, and semaglutide’s link to reduced suicidality shaped psychiatry headlines in March 2026.

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

In part 3 of an interview, Michael E. Thase, MD, discusses retreatment timing, safety monitoring, and research priorities following phase 2b GH001 data.

An interview with Thase explores rapid antidepressant effects and real-world considerations for single-day individualized GH001 dosing in TRD.

Analysis of 75,064 UK Biobank participants found late-onset depression associated with worse fluid intelligence and visuospatial memory and a 42–52% increased dementia risk.

Inhaled GH001 achieved 57.5% remission by day 8 in TRD with a large effect size vs placebo; Thase discusses interpretation, unblinding, and phase 3 implications.

As patients increasingly turn to ChatGPT for mental health support, psychiatrists and ethicists weigh the clinical risks, ethical concerns, and what clinicians should do next.

Study shows microglia-driven hippocampal remodeling may connect chronic pain to depression, highlighting the importance of timing for behavioral interventions.

National cohort study finds semaglutide tied to reduced depression, anxiety, and self-harm risk in patients with diabetes and comorbid mental illness.

Study reveals chronic pain reshapes hippocampus, driving depression risk. Microglia may be a therapeutic target, says Xiao.

Accelerated rTMS shows comparable efficacy to standard care, with delayed response in some patients and no clear predictors of early benefit.

New study finds GLP-1 RAs are associated with lower anxiety, suicidality, and sick leave in patients with diabetes and mental illness.

Findings suggest psychedelics match antidepressants for symptom relief, with future research needed on real-world use and functional outcomes.

Meta-analysis shows psychedelic-assisted therapy offers similar symptom improvement to open-label antidepressants under equal unblinding conditions.

Accelerated 5×5 rTMS delivers comparable outcomes to standard protocols, offering faster treatment with key tradeoffs in cost, access, and response timing.

BrainsWay’s SWIFT protocol reduced treatment visits from ~36 to 6 while maintaining response and remission rates in a randomized multisite trial.

In Medical Ethics Unpacked, hosts and guest Rose Onyeali, MD, discuss how solitary confinement in prisons may accelerate physical decline and worsen cognitive health.

In this episode, experts discuss solitary confinement, aging in prison, and gaps in care for incarcerated populations.

The FDA approval of milsaperidone and a pair of positive trials in depression signal a month of progress in psychiatry.

Gu explains how addiction drives GI and liver disease and why integrated care is key to improving outcomes and survival.

FDA clears iloperidone metabolite, milsaperidone, for acute bipolar I disorder and schizophrenia, expanding treatment options.

Levine discusses 24-hour adverse event resolution, retreatment questions, and scalability of supervised psilocybin therapy for treatment-resistant depression.

Levine breaks down Compass Pathways’ phase 3 data on COMP360, highlighting next-day onset and sustained symptom improvement through 26 weeks.